Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report, by Therapeutic Area (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barré Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN), by Dosage Form, by Type of Immunoglobulin, End User, By Region, Forecasts, 2025-2034
Segmentation of Intravenous Immunoglobulin Market-
Intravenous Immunoglobulin Market- By Therapeutic Area
- Primary Immunodeficiency
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Guillain-Barré Syndrome (GBS)
- Immune Thrombocytopenic Purpura (ITP)
- Multifocal Motor Neuropathy (MMN)
Intravenous Immunoglobulin Market- By Dosage Form
- Liquid
- Lyophilized
Intravenous Immunoglobulin Market- By Immunoglobulin
- IgG
- IgA
- IgM
- IgE
- IgD
Intravenous Immunoglobulin Market- By End User
- Hospitals
- Clinics
- Homecare
- Other End Users
Intravenous Immunoglobulin Market By Region-
North America-
- The US
- Canada
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
Rest of Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Intravenous Immunoglobulin Market Snapshot
Chapter 4. Global Intravenous Immunoglobulin Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Therapeutic Area Estimates & Trend Analysis
5.1. by Therapeutic Area & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Therapeutic Area:
5.2.1. Primary Immunodeficiency
5.2.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.2.3. Guillain-Barré Syndrome (GBS)
5.2.4. Immune Thrombocytopenic Purpura (ITP)
5.2.5. Multifocal Motor Neuropathy (MMN)
Chapter 6. Market Segmentation 2: by Dosage Form Estimates & Trend Analysis
6.1. by Dosage Form & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Dosage Form:
6.2.1. Liquid
6.2.2. Lyophilized
Chapter 7. Market Segmentation 3: by Immunoglobulin Estimates & Trend Analysis
7.1. by Immunoglobulin & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Immunoglobulin:
7.2.1. IgG
7.2.2. IgA
7.2.3. IgM
7.2.4. IgE
7.2.5. IgD
Chapter 8. Market Segmentation 4: by End User Estimates & Trend Analysis
8.1. by End User & Market Share, 2024 & 2034
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by End User:
8.2.1. Hospitals
8.2.2. Clinics
8.2.3. Homecare
8.2.4. Other End Users
Chapter 9. Intravenous Immunoglobulin Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
9.1.2. North America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2021-2034
9.1.3. North America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Type of Immunoglobulin, 2021-2034
9.1.4. North America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.1.5. North America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.2. Europe
9.2.1. Europe Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
9.2.2. Europe Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2021-2034
9.2.3. Europe Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Type of Immunoglobulin, 2021-2034
9.2.4. Europe Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.2.5. Europe Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.3. Asia Pacific
9.3.1. Asia Pacific Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
9.3.2. Asia Pacific Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2021-2034
9.3.3. Asia-Pacific Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Type of Immunoglobulin, 2021-2034
9.3.4. Asia-Pacific Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.3.5. Asia Pacific Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.4. Latin America
9.4.1. Latin America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
9.4.2. Latin America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2021-2034
9.4.3. Latin America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Type of Immunoglobulin, 2021-2034
9.4.4. Latin America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.4.5. Latin America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.5. Middle East & Africa
9.5.1. Middle East & Africa Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
9.5.2. Middle East & Africa Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2021-2034
9.5.3. Middle East & Africa Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Type of Immunoglobulin, 2021-2034
9.5.4. Middle East & Africa Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.5.5. Middle East & Africa Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Bio Products Laboratory
10.2.2. Biotest
10.2.3. China biologics Products Holdings
10.2.4. CSL Behring
10.2.5. Grifols
10.2.6. Kedrion
10.2.7. LFB
10.2.8. Octapharma
10.2.9. Shanghai RAAS Blood products
10.2.10. Shire
10.2.11. Other Prominent Players
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Intravenous Immunoglobulin Market Size is valued at USD 13.26 billion in 2024 and is predicted to reach USD 25.46 billion by the year 2034
Intravenous Immunoglobulin Market expected to grow at a 7.0% CAGR during the forecast period for 2025-2034
Biotest AG, Octapharma AG, LFB Biotechnologies, Grifols SA, CSL Behring, China Biologics Products Inc., Kedrion Biopharma,
Intravenous Immunoglobulin market is segmented into therapeutic area, dosage form, type of immunoglobulin, end user.
North America region is leading the Intravenous Immunoglobulin Market.